New treatment for melanoma patients who can't use immunotherapy
Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy
This study is testing a new pill called LNS8801 for people with skin cancer who can’t handle current immunotherapy treatments because of bad side effects, aiming to make cancer treatment easier and more effective for those who need better options.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Linnaeus Therapeutics INC NIH-funded |
| Lab location | 1 site (Haddonfield, United States) |
| Project ID | NIH-11062612 on NIH RePORTER |
What this research studies
This research focuses on developing a new oral medication called LNS8801 for patients with cutaneous melanoma who are unable to tolerate existing immunotherapy options due to severe side effects. The approach involves targeting a specific receptor in cancer cells to enhance treatment effectiveness while minimizing adverse reactions. By combining LNS8801 with standard cancer therapies, the goal is to improve patient outcomes and provide a well-tolerated alternative for those who have limited options. The research will involve clinical trials to assess the safety and efficacy of this new treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cutaneous melanoma who have experienced significant side effects from immunotherapy and are seeking alternative treatment options.
Not a fit: Patients with melanoma who are currently responding well to existing immunotherapy treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for melanoma patients who cannot tolerate current immunotherapies.
How similar studies have performed: Previous research has shown promise with similar approaches targeting the GPER receptor, indicating potential for success in this novel treatment.
Where this research is happening
Haddonfield, United States
- Linnaeus Therapeutics INC — Haddonfield, United States (Active)
Researchers
- Principal investigator: Garyantes, Tina — Linnaeus Therapeutics INC
- Study coordinator: Garyantes, Tina
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.